Endothelium, Platelets, and Coagulation Factors as the Three Vital Components for Diagnosing Bleeding Disorders: A Simplified Perspective with Clinical Relevance

Abhinav Bhattarai, Sangam Shah, Sara Bagherieh, Omid Mirmosayyeb, Sangharsha Thapa, Sandip Paudel, Pawan Gyawali, and Pitambar Khanal

1 Institute of Medicine, Tribhuvan University, Maharajgunj 44600, Nepal
2 Isfahan Neuroscience Research Center, Isfahan, Iran
3 Department of Neurology, Jacobs Comprehensive MS Treatment and Research Center, Jacobs School of Medicine and Biomedical Sciences, University, Buffalo, State University of NY, Buffalo, NY, USA

Correspondence should be addressed to Sangam Shah; sangam.shah.1997@gmail.com

Received 22 June 2022; Revised 31 July 2022; Accepted 12 August 2022; Published 27 August 2022

Copyright © 2022 Abhinav Bhattarai et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Bleeding disorders are a major group of hematological disorders, which are highly prevalent in the world. Excessive bleeding can result in serious consequences including hypoperfusion and cardiac arrest. The body has its innate mechanism to control excessive bleeding, such consequences seldom occur [1]. This mechanism by which the body renders the bleeding concluded is hemostasis. Hemostasis is achieved in two major steps, the formation of the primary and secondary hemostatic plugs. Endothelium, platelets, and coagulation factors are three components involved in hemostasis. Endothelium and platelets have a major role in forming the primary hemostatic plug. Consequently, the first step in investigating a bleeding disorder is platelet count. Despite normal platelet count, abnormality in the primary hemostatic plug may arise due to functional defects of the platelets including adhesion, activation, and aggregation. Von Willebrand disease (VWD) is an endothelial defect and the most prevalent inherited defect in coagulation. Abnormalities in the secondary hemostatic plug are largely due to coagulation factor deficiencies, and, to a lesser extent, the presence of inhibitors. Techniques involving viscoelastics have been aiding in rapid diagnosis and are useful in point-of-care testing. This article discusses the investigation of bleeding disorders from the perspective of the endothelium, platelet, and coagulation factor physiology. These three components should be properly investigated to achieve the definitive diagnosis of bleeding disorders.

1. Introduction

Bleeding is the spontaneous escape of blood from the blood vessels following trauma. Excessive loss of blood from the vessels may lead to serious consequences including reduced blood pressure, tissue hypoperfusion, and cardiac arrest. Owing to the body for its innate mechanism for controlling excess bleeding, such consequences seldom occur [1]. The mechanism by which the body renders the bleeding concluded is hemostasis. Hemostasis is accomplished in four distinct stages, starting from blood vessel constriction, formation of the platelet plug, formation of a stable insoluble fibrin clot, and finally removal of the fibrin clot [2]. Following bleeding, there is vasoconstriction, followed by adhesion, activation, and aggregation of platelets, occluding the site of bleeding. This process is referred to as the primary hemostatic plug formation. The coagulation factors are then activated, forming thrombin, which in turn forms insoluble fibrin from fibrinogen. Afterward, Factor XIII, which is activated by thrombin, strengthens the fibrin clot by cross-linkage, forming the secondary hemostatic plug [3].

The entire process is not over until the fibrin clot formation is inhibited by fibrinolysis. Following bleeding, the clotting mechanism cannot be set perpetual, and the
2.1. Endothelial Defect. The endothelium possesses both coagulatory and anticoagulatory functions, and the clotting process is a balance between both of them. Endothelium, on one hand, promotes clotting process by synthesizing the von Willebrand factor (VWF) and platelet adhesion factors, and on the other, impedes platelet adhesion and clotting via prostacyclins, nitric oxides, ecto-ADPase, and tissue plasminogen activator (t-PA) [11–14]. In favor of clotting, the endothelial cells store VWF in a specified organelle, Weibel-Palade bodies [15]. Upon trauma, the membranes of the endothelial cells are disrupted resulting in the exposure of VWF into the blood stream. The VWF is a potent biomolecule that on interaction with the exposed sub-endothelial collagen and high shear forces has a strong affinity to binding to the glycoprotein Ib (gplb) of platelets causing platelet adhesion and activation [16]. Inherited defect in VWF is most commonly encountered.

2.1.1. Von Willebrand Disease (VWD). VWD is caused by the deficiency or the entire absence of VWF [17]. The first indication of VWD is a prolonged BT with normal platelet count. VWD is confirmed by the plasma estimation of VWF antigen (VWF:Ag) testing. Most laboratories employ latex immunoassay and Enzyme-Linked Immunosorbent Assay (ELISA) for the estimation [18]. Clinicians and laboratories should however be aware that VWF:Ag solely cannot distinguish between VWD subtypes. Since VWD types 1 and 3 are quantitative defects, VWF:Ag estimation is suitable in the context, whereas since VWD type 2 is purely a qualitative defect, VWF:Ag may appear normal in most cases.

To accomplish the differentiation of the VWD subtypes, platelet-binding ability (measure of activity) of VWF via ristocetin is a classical yet effective technique where patient’s plasma is allowed to interact with normal platelets in the presence of ristocetin. Enhanced activity is a feature in Type 2B VWD. However, the technique holds some drawbacks including low sensitivity, poor reproducibility, higher variation, and false low VWF activity. More recent and reliable techniques involving recombinant platelet glycoprotein gplb have been developed to overcome the drawbacks of the classical technique. Wild-type gplb is now available that is more specific and overtakes the sensitivity of the classical technique. The recombinant wild-type gplb is used as an alternative to platelets, but the presence of ristocetin is still required. In addition, “gain-to-function” mutated gplb (gplbM) is also commercially manufactured which even obviates the requirement of ristocetin in platelet-binding assays [19, 20].

Aforementioned platelet-binding assays in conjunction with VWF:Ag are further a useful tool in the distinction of VWD subtypes. The ratio of the VWD activity and antigen (activity/antigen) is recommended since few patients with type 2 VWD present both normal activity and antigen, with an abnormal ratio. Furthermore, types 1 and 2 can be accurately identified based on the activity-antigen ratio. According to the American Society of Hematology (ASH), the International Society on Thrombosis and Hemostasis (ISTH), the National Hemophilia Foundation (NHF), and the World Federation of Hemophilia (WFH)’s published guidelines, the activity to antigen ratio of less than 0.7 is consistent with type 2 VWD. On the other hand, ratio greater than 0.7 is a feature in type 1 VWD [21].

---

**Figure 1**: Overview on hemostasis.
2.2.1. *WT*_hrombocytopenia (Quantitative Defect).

Platelet Defect form of the disease [23, 24]. Deficiency of larger multimers is associated with more severe Americanalysis is not incorporated into routine testing due to the costliness and is only performed for specific purposes. Deficiency of larger multimers is associated with more severe form of the disease [23, 24].

2.2. Platelet Defect

2.2.1. *WT*_hrombocytopenia (Quantitative Defect). The first step in investigating bleeding disorder is accessing platelet count [25]. Thrombocytopenia involves platelet count below 150,000/mm³ and is the most common cause of bleeding [26]. Thrombocytopenia may be caused by both inherited and acquired etiologies [27, 28]. Accessing the platelet count is important prior to initiating the detailed investigation for the bleeding disorder. Clinicians must assure that the patients are not under any thrombolytic and anticoagulation drugs prior investigating [29, 30]. The various causes of thrombocytopenia are displayed in Table 1 [31–36].

2.2.2. Functional (Qualitative) Defect. With a normal platelet count, bleeding may arise when there is any functional abnormality in platelets. Functional defects refer to the defects in adhesion, activation, and aggregation process during platelet plug formation [37]. The Platelet Function Analyzer-100 (PFA-100) is a useful tool in screening the phenomenon of adhesion, activation, and aggregation [38]. It consists of an aperture coated with essential adhesion factors of platelets including collagen, ADP, and epinephrine. When blood is allowed to pass, the platelets bind to these surface agonists, occluding the aperture, and the "closure time" is noted. Prolongation of the closure time indicates defective platelet function [39].

As already discussed above, VWD can impede platelet adhesion. However, there are other platelet factors responsible for adhesion including the glycoprotein Ibf (gpIbf). Inherited defect in the gpIbf results in Bernard-Soulier Syndrome [40]. This condition can be diagnosed by the flow cytometric analysis of the deficient gpIbf on platelet surface [41]. Also, the syndrome presents with giant platelets and thus a low platelet count which aid in suspicion [41]. The distinction between VWD and Bernard-Soulier syndrome can be accomplished by the ristocetin-induced platelet aggregation. Both of these conditions will exhibit a defective aggregation and can be distinguished since the addition of normal plasma corrects the defective ristocetin-induced aggregation in VWD and not in Bernard-Soulier syndrome [42]. Ristocetin cofactor assay (RCo) is a similar assay with an advantage of allowing differentiation of VWD subtypes based on the ratio of VWF level and extent of ristocetin activity (vWF: RCo) [43]. Further confirmation can be done using flow cytometry.

Storage deficiency has also been a major concern since it can cause activation defect. Platelets primarily possess three types of granules: alpha and dense granules and lysosomes [44]. The alpha granules store P-selectin, fibronectin, PDGF-4, and TGF-β. The dense granules store ADP, histamine, serotonin, and epinephrine. The dense granules are responsible to a larger extent for platelet activation [45]. Storage deficiency can lead to poorly platelet aggregation. Platelet aggregation is investigated using an aggregometer which works on the principle that the transmission of light increases as platelets aggregate [46, 47]. Another glycoprotein, activated integrin αIIbβ3, commonly known as gpIbf/IIIa on platelets, is responsible for platelet aggregation by cross-linking platelets with fibrinogen [48]. Defective gpIbf/IIIa on platelets results in inadequate aggregation, and this condition is called Glanzmann’s thrombasthenia [49]. Flow cytometric analysis of gpIbf/IIIa aids in diagnosing Glanzmann’s thrombasthenia [50]. In brief, any abnormalities in the alpha granules, vWF, fibrinogen, dense granules, Ca²⁺, polyphosphates, and ATP can hinder platelet aggregation. Another important aspect that may hinder normal platelet function is the consumption of antiplatelet effects of drugs including aspirin. Aspirin acts by the acetylation of the platelet cyclooxygenase enzymes leading to diminished formation of prostaglandins and thromboxane from arachidonic acid, ultimately hindering platelet aggregation. Generally, platelet aggregation is normalized after 96 hours of the latest aspirin ingestion [51]. Furthermore, the presence of a high amount of FDPs competes against fibrinogen and binds to platelets inhibiting platelet aggregation [52].

2.2.3. The ISTH-BAT Score in Suspected Inherited Bleeding Defect. In 2010, the International Society of Thrombosis and Hemostasis (ISTH) proposed a checklist as a bleeding assessment tool (BAT) for the screening of inherited bleeding

| Table 1: Table displaying various causes behind thrombocytopenia. |
|-------------------------------------------------------------|
| **Increased destruction**                                    |
| **Immune**                                                   |
| Idiopathic thrombocytopenic purpura systemic lupus erythematosus drugs: heparin, penicillin, quinidine, quinine infections: HIV, malaria post-transfusion purpura, and neonatal alloimmune purpura. |
| **Hereditary**                                               |
| Fanconi’s anemia and Wiskott-Aldrich syndrome                |
| **Nonimmune**                                               |
| Disseminated intravascular coagulation, thrombotic thrombocytopenic purpura, hemolytic uremic syndrome, and giant hemangioma |
| **Acquired**                                                |
| Aplastic anemia, megaloblastic anemia, hematological malignancies, thrombolytic drugs, and viral infections |
| **Others**                                                  |
| Dilutional thrombocytopenia following massive blood transfusion, increased sequestration in hypersplenism, Bernard-Soulier syndrome, von Willebrand disease type 2B, chemotherapy-induced thrombocytopenia (CIT), and radiation-induced thrombocytopenia (RIT). |
disorder [53]. The checklist assesses the potentiality of an underlying bleeding disorder via symptoms and history of the patient under 14 distinct categories. The categories include excess bleeding history from skin, joints, nose, oral cavity, dental procedures, gastrointestinal and urogenital tracts, excessive menstrual bleeding, past surgeries, and transfusion requirements [54]. The main aim of the assessment tool is to lower the need of laborious laboratory tests. The ISTH-BAT scores have shown significant associations in underlying bleeding disorders in various studies. In a study by Adler et al. [55] conducted in 555 patients with suspected bleeding disorder, 288 (51.9%) patients were diagnosed with a bleeding disorder with the highest frequencies being observed in platelet function defects and vWD. However, Fasulo et al. [56] showed contrary reports in his study. The ASH Clinical News in 2019 published that ISTH-BAT is validated for the suspicion of vWD, and its use for platelet function defect has not been investigated [57]. Pathare et al. [58] also presented supportive evidence of significant correlation of the ISTH-BAT with vWF:Ag measurement. Currently, the topic is still a matter of research, and no universal validation has been announced.

2.3. Coagulation Factor Defect. A majority of coagulation factors except fibrinogen are not involved in the primary hemostatic plug formation. Fibrinogen is a protein produced by the liver and is required for the cross-linking of platelets during the aggregation process. Hence, states where the liver function is compromised can greatly influence plasma fibrinogen concentration [59–61]. Two types of fibrinogen assay are now widely used. One based on the thrombin time method and another based on latex agglutination. However, thrombin time method has an advantage that it estimates only the functional fibrinogen in the plasma while the latex-based assay estimates all functional as well as nonfunctional fibrinogens which may be encountered in dysfibrinogenemia. In dysfibrinogenemia, there are high chances that the latex-based assay may overestimate the functional fibrinogen by including the nonfunctional as well [62, 63]. Estimation of FDPs and specifically D-dimer can be performed as these can impede coagulation by competing against the fibrinogen [6]. FDPs are the indication of fibrinolysis and are significantly elevated in disseminated intravascular coagulation (DIC) (Fibrin Degradation Products [64]).

3. Abnormalities in the Secondary Hemostatic Plug Formation

Affected secondary hemostatic plug formation is mainly due to the deficiency of coagulation factors and has less to do with the endothelium and platelets. The first features are seen during the screening tests as prothrombin time (PT) or activated partial prothrombin time (APTT) or both shows abnormal results. Thrombin time (TT) is specific to screening for thrombin formation. Clotting time (CT) is also performed by most of the laboratories but may mislead the diagnosis since abnormal results are obtained only after the factor deficiency is huge that its plasma activity is <5% [65]. While most often the abnormal results arise due to one or multiple factor deficiencies, circulating inhibitors result to a lesser extent [66]. Clinicians should however remember that it is important to rule out the liver involvement in cases of prolonged PT or APTT. The liver is responsible for the synthesis of coagulation factors [67], and chronic liver diseases result in decreased synthesis of coagulation factors. Assessment of the liver function tests (LFTs) should be performed first prior to in-depth investigation of a coagulopathy [68, 69]. Another thing to remember here is that when LFTs are normal, vitamin K deficiency might be the reason. Vitamin K is required for the gamma-carboxylation of the coagulation factors so that they can function normally. Assessment of PT/APTT after vitamin K supplementation can also be performed [70–72]. PT is more sensitive to vitamin K deficiency since the factor VII which is the initiating factor of the extrinsic pathway is vitamin K dependent [73]. One more important fact to know is that consumption of aspirin will also prolong these tests [74]. These screening tests should be performed at least twice before starting the treatment to ensure that the abnormal results are not due to preanalytical, analytical, and postanalytical errors. If these parameters are normal, then the clinician can proceed to the in-depth investigation by confirmatory testing.

3.1. Identification of the Etiology. The first step is to identify whether the abnormal results are due to factor(s) deficiency or presence of inhibitor(s). The PT/APTT mixing tests are commonly performed for the screening. When normal plasma is mixed with the test plasma, then the factors are supplied by the normal plasma which is supposed to correct the prolonged test. If there are inhibitors present, even the addition normal plasma cannot correct it and the test remains prolonged [75, 76]. However, confusion might arise in case of delayed acting inhibitors. In the case, the test initially shows correction and points out underlying factor deficiency but later is prolonged again due to the action of delayed acting inhibitor [77]. That is why testing mixed test plasma after 2 hours of incubation is important to detect these inhibitors.

3.2. Confirmatory Tests of the Secondary Hemostatic Defects. Once the etiology is identified, the absence of the specific factor of the presence of the inhibitor can be tested. Factor assays are widely performed in routine laboratories today. Factor VIII deficiency is the most prevalent which is termed as hemophilia A [78]; [79]. It is an X-linked disorder that predominantly affects the males with a global prevalence of 1 in 5000 male births [80]; [81]; [17]. In von Willebrand disease, factor VIII concentration is low since a fraction of it remains bound to VWF which protects from destruction in circulation. A less common disease is hemophilia B which is due to factor IX deficiency and is seen in approximately 1 in 25000 male births [82]. Both of these diseases are suspected
by isolated prolongation of PT. Apart from these, factor XI, V, and X deficiencies may be encountered but are very occasional [83, 84]. Most of the laboratories utilize factor-deficient plasma reference graph method that measures factor activity and has shown better performance [85].

Test plasma sometimes present normal findings with normal factor activity and absence of inhibitors. However, prolonged PT/APTT is obtained. In such cases, hypofibrinogenemia is the cause which results from DIC or chronic liver diseases [86]. As discussed earlier, the thrombin time method for fibrinogen as proposed by Clauss is preferred since it provides the measure of functional fibrinogen. Again, the thrombin time method for fibrinogen may be prolonged even in normal fibrinogen concentrations when heparin is present in the blood which inhibits thrombin formation [87]. The reptilase time has been proposed that can successfully distinguish between hypofibrinogenemia and heparin. Reptilase is the venom from the snake Bothrops atrox that can interfere with the action of heparin [88]. Alike mixing tests discussed above, the test plasma is mixed with reptilase and the PT/APTT is retested. In case of heparin, the tests which were previously prolonged are now corrected to normal reference range. The tests remain prolonged in case of dysfibrinogenemia, hypofibrinogenemia, or afibrinogenemia [89].

Various types of inhibitors are identified that are responsible for the prolonged coagulation tests and are categorized into specific and nonspecific inhibitors [90]; [91]. Anti-factor VIII antibody is the most common specific inhibitor and is likely to be present in hemophilia A and in individuals receiving multiple transfusions [92–94]. Lupus anticoagulant is a nonspecific inhibitor which is an antiphospholipid antibody [95]. Phospholipids confer a negatively charged surface on the platelets and bind coagulation factors via calcium [96]. While lupus anticoagulants present paradoxically prolonged coagulation tests on one hand, a strong risk of arterial and venous thrombosis exists on the other [97]. Diluted Russell Viper’s Venom Time (dRVVT) is nowadays popular in detecting lupus anticoagulant. The test is not affected by factor VIII or IX inhibitors and generates sensitive and specific results [98]. Lupus anticoagulant is commonly encountered in systemic lupus erythematosus (SLE), autoimmune disorders, malignancies, and administration of phenytoin, quinine, procainamide, chlorpromazine, and hydralazine [99].

4. Disseminated Intravascular Coagulation (DIC): An Overlapping Presenter

DIC is a systemic manifestation of underlying conditions that result in consumption of platelets by extensive activation of the coagulation cascade [100]. Some of the common triggers of DIC are brain trauma, ongoing hemolysis, blood stream infection, pre-eclampsia, other hypertensive diseases complicating pregnancy, snake bite, acute promyelocytic leukemia, and recent surgery [101, 102]. DIC presents with abnormalities in both primary and secondary hemostatic plug defects due to consumption of platelets as well as coagulation factors. When tests for both categories are abnormal, DIC can be suspected given a history of trigger [103]. Microangiopathic hemolytic anemia is a common manifestation of DIC due to RBC injury by microclots in vessels [104]; [105]. Peripheral blood film examination reveals fragmented red cells “schistocytes” in large numbers [106]. That’s why, a peripheral blood film is important to examine at the initial investigation stage of coagulopathies so that indication of DIC can be obtained. Another distinguishing feature of DIC is the elevated blood fibrin degradation products (FDPs) due to destruction of the huge amount of fibrin formed (“Fibrin Degradation Products” [64]). D-dimer is the end product of fibrin destruction and is widely measured using monoclonal antibody latex agglutination [107, 108]. Practically, all FDPs do not end as d-dimers, and some of them remain as X and Y fragments Figure 2, especially in early DIC and the estimation of d-dimer alone in such situation can underestimate the extent of DIC [90]. Occasionally, soluble fibrin monomers may arise which can be detected by the ethanol and protamine sulfate gelation test, and a positive gelification is suggestive of intravascular coagulation [109, 110].

5. Viscoelastic Hemostatic Assays in Diagnosing Bleeding Disorders

Studying the viscoelastic property of blood has been gaining popularity in recent days. As blood starts to coagulate, there appears an increase in the viscoelasticity, and it is reduced as fibrinolysis sets in and the clot is eliminated. Some laboratories utilize the principle as thromboelastography (TEG) [111, 112]. TEG is however not a novel technique and was developed in 1948 [112]. The architecture consists of a cup and a pin suspended into the cup. The cup oscillates across the pin. The working design is similar to a seismograph. In TEG, the test blood is filled in the cup and is oscillated across the pin suspended vertically into the blood. As clot formation begins, it adheres to the pin and makes it move along with it [113]. As the pin moves, a graph is generated [114] as shown in Figure 3.
As the clot gets strengthened, the amplitude increases proportionally. The time from the start of oscillation to the appearance of first amplitude is the clotting time. The maximum amplitude is when the clot formation is completed. As fibrinolysis sets in, the clot's adherence to the pin is reduced and so is the amplitude. When fibrinolysis is completed, the pin is again motionless and the amplitude is zero. The time between the highest amplitude and its nullification is the time for complete fibrinolysis [115]. Since the test possesses a rapid turnaround time of 15 to 20 minutes, it can be used as a point-of-care testing. Rotational thromboelastometry (ROTEM) is also a similar procedure which is used. The difference between TEG and ROTEM is that the cup is the one that oscillates across the pin in TEG while in ROTEM, the pin oscillates and the cup is fixed [116–118].

A schematic summary of different coagulation tests in accordance to the steps in hemostasis is shown in Figure 4).

6. Conclusion

Bleeding disorders are one of the most prevalent hematological disorders worldwide. The article simplifies the diagnosis of the vague term “bleeding disorder” into three basic yet vital components, including endothelium, platelets, and coagulation factors. It is important to understand the physiology of each of the subgroups and know how an individual defect affects the entire coagulation system of the body. When investigation is carried out in this perspective, there are few chances to miss the definitive diagnosis. Viscoelastic methods allow the study of complete physiology of blood clotting of the patient including fibrinolysis. Interpreting bleeding disorders can be erroneous when the defects in these components are not properly and entirely investigated. This perspective enables clinicians and laboratories to accurately identify the defect and guides to the selection of specific treatment options for the patient.

Data Availability

All data used to support the findings of the study can be obtained within the article.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors’ Contributions

AB, ST, SB, OM, and SP wrote the entire manuscript. SS, PG, and PK reviewed and edited the manuscript.
References

[1] T. Römer and A. Kelley, "Bleeding disorders," Gynakologische Endokrinologie, vol. 17, no. 1, pp. 25–38, 2019.

[2] A. LaPeluca and H. D. Dave, "Physiology, Hemostasis," StatPearls, StatPearls Publishing, Treasure Island, FL, USA, 2022.

[3] J. Hawiger, "Formation and Regulation of Platelet and Fibrin Hemostatic Plug," Human Pathology, vol. 18, no. 2, pp. 111–122, 1987.

[4] The Significance of Fibrinolysis, "The Significance of Fibrinolysis," Proceedings of the Royal Society of London. Series B. Biological Sciences, vol. 173, no. 1032, pp. 311–315, 1969.

[5] J. W. Weisel and R. I. Litvinov, Mechanisms of Fibrinolysis and Basic Principles of Management, Hemostasis and Thrombosis, Las Vegas, NV, USA, 2014.

[6] L. K. Jennings and M. Mc C. White, "Platelet Aggregation," Platelets, vol. 10, pp. 495–507, 2007.

[7] V. McDonald and S. J. Machin, "Inherited and Acquired Coagulation Disorders," Practical Transfusion Medicine, pp. 261–275, 4th edition, 2013.

[8] U. Göbel, H. P. Volkmer, C. Petrich, and H. von Voss, "A comparison of different methods of measuring bleeding time (Author’s Trans.)," Deutsche Medizinische Wochenschrift (1946), vol. 101, no. 3, pp. 81–83, 1976.

[9] A. P. Russeau, H. Vall, and B. Manna, "Bleeding Time," StatPearls, StatPearls Publishing, Treasure Island, FL, USA, 2021.

[10] Medlineplus, "Bleeding into the skin: MedlinePlus medical encyclopedia," 2022, https://medlineplus.govency/article/003235.htm.

[11] N. J. Leeper, L. Zhu, and Early Career, "Antithrombotic and Prothrombotic Activities of the Vascular Endothelium," Biomedicine & Pharmacotherapy, vol. 54, no. 2, pp. 107–111, 2000.

[12] M. Wang, H. Hao, N. J. Leeper, L. Zhu, and Early Career Committee, "Thrombotic Regulation From the Endothelial Cell Perspectives," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 38, no. 6, pp. E90–E95, 2018.

[13] J. W. You, H. Teoh, and S. Verma, "Endothelial Cell Control of Thrombosis," BMC Cardiovascular Disorders, vol. 15, no. 1, pp. 130–211, 2015.

[14] D. P. Kaufman, T. Sanvictores, and M. Costanza, "Weibel Palade Bodies," StatPearls, StatPearls Publishing, Treasure Island, FL, USA, 2022.

[15] A. B. Federici, "The von Willebrand factor from basic mechanisms to clinical practice," Blood Transfusion, vol. 9, no. Suppl 2, p. s1, 2011.

[16] CDC, "What Is von Willebrand Disease? | CDC," 2022, https://www.cdc.govncbd33dvdwdefaults.html.

[17] E. J. Favaloro, S. Mohammed, and J. Patzke, "Laboratory testing for von Willebrand factor Antigen (VWF:Ag)," Methods in Molecular Biology (Clifton, N.J.), vol. 1646, pp. 403–416, 2017.

[18] J. Patzke and E. J. Favaloro, "Laboratory Testing for von Willebrand Factor Activity by Glycoprotein Ib Binding Assays (VWF-GPIb)," Methods in Molecular Biology (Clifton, N.J.), vol. 1646, pp. 453–460, 2017.

[19] A. C. Weyand and V. H. Flood, "Von Willebrand Disease: Current Status of Diagnosis and Management," Hematology/Oncology Clinics of North America, vol. 35, no. 6, pp. 1085–1101, 2021.

[20] A. D. Michelson, "Platelets," 1990, https://www.sciencedirect.com/book/9780128134566/platelets?via=inihub.

[21] Nhlbi and Nih, "Platelet Disorders Thrombocytopenia | NHLBI, NIH," 2022, https://www.nhlbi.nih.gov/health/thrombocytopenia.

[22] T. Bakchoul and A. Greinacher, "Acquired thrombocytopenia." Molecular and cellular Biology of platelet formation, Implications in Health and disease, vol. 327–49, 2017.

[23] E. L. Chou and N. V. Morgan, "Inherited thrombocytopenia: update on genes and genetic variants which may Be associated with bleeding," Frontiers in Cardiovascular Medicine, vol. 6, no. June, p. 80, 2019.

[24] K. Harter, M. Levine, and S. O. Henderson, "Anticoagulation Drug Therapy: A Review," Western Journal of Emergency Medicine, vol. 16, no. 1, pp. 11–17, 2015.

[25] O. Hidayat, J. Zlamal, P. Aidery, and T. Bakchoul, "Acquired Immune Thrombocytopenia: An Update on Aspects of Diagnosis and Management Relevant for Intensive Care Medicine," Deutsche Medizinische Wochenschrift (1946), vol. 145, no. 11, pp. 747–753, 2020.

[26] Ogbykey, "Disorders of platelets obgyn key," 2022, https://ogbykey.com/disorders-of-platelets/.

[27] S. M. Kawthalkar, Essentials of Hematology, p. 602, Gouridevi Institute of Medical Sciences and Hospitals, Rajbhand, West Bengal, 2020.

[28] S. M. K. Fang, K. P. G. van der Meulen, and S. O. Henderson, "Anticoagulation Drug Therapy: A Review," Western Journal of Emergency Medicine, vol. 16, no. 1, pp. 11–17, 2015.

[29] O. Hidayat, J. Zlamal, P. Aidery, and T. Bakchoul, "Acquired Immune Thrombocytopenia: An Update on Aspects of Diagnosis and Management Relevant for Intensive Care Medicine," Deutsche Medizinische Wochenschrift (1946), vol. 145, no. 11, pp. 747–753, 2020.

[30] Ogbykey, "Disorders of platelets obgyn key," 2022, https://ogbykey.com/disorders-of-platelets/.

[31] S. M. Kawthalkar, Essentials of Hematology, p. 602, Gouridevi Institute of Medical Sciences and Hospitals, Rajbhand, West Bengal, 2020.

[32] S. M. K. Fang, K. P. G. van der Meulen, and S. O. Henderson, "Anticoagulation Drug Therapy: A Review," Western Journal of Emergency Medicine, vol. 16, no. 1, pp. 11–17, 2015.

[33] O. Hidayat, J. Zlamal, P. Aidery, and T. Bakchoul, "Acquired Immune Thrombocytopenia: An Update on Aspects of Diagnosis and Management Relevant for Intensive Care Medicine," Deutsche Medizinische Wochenschrift (1946), vol. 145, no. 11, pp. 747–753, 2020.

[34] Ogbykey, "Disorders of platelets obgyn key," 2022, https://ogbykey.com/disorders-of-platelets/.

[35] S. M. Kawthalkar, Essentials of Hematology, p. 602, Gouridevi Institute of Medical Sciences and Hospitals, Rajbhand, West Bengal, 2020.

[36] S. M. K. Fang, K. P. G. van der Meulen, and S. O. Henderson, "Anticoagulation Drug Therapy: A Review," Western Journal of Emergency Medicine, vol. 16, no. 1, pp. 11–17, 2015.

[37] O. Hidayat, J. Zlamal, P. Aidery, and T. Bakchoul, "Acquired Immune Thrombocytopenia: An Update on Aspects of Diagnosis and Management Relevant for Intensive Care Medicine," Deutsche Medizinische Wochenschrift (1946), vol. 145, no. 11, pp. 747–753, 2020.

[38] Ogbykey, "Disorders of platelets obgyn key," 2022, https://ogbykey.com/disorders-of-platelets/.

[39] S. M. Kawthalkar, Essentials of Hematology, p. 602, Gouridevi Institute of Medical Sciences and Hospitals, Rajbhand, West Bengal, 2020.

[40] S. M. K. Fang, K. P. G. van der Meulen, and S. O. Henderson, "Anticoagulation Drug Therapy: A Review," Western Journal of Emergency Medicine, vol. 16, no. 1, pp. 11–17, 2015.

[41] O. Hidayat, J. Zlamal, P. Aidery, and T. Bakchoul, "Acquired Immune Thrombocytopenia: An Update on Aspects of Diagnosis and Management Relevant for Intensive Care Medicine," Deutsche Medizinische Wochenschrift (1946), vol. 145, no. 11, pp. 747–753, 2020.

[42] Ogbykey, "Disorders of platelets obgyn key," 2022, https://ogbykey.com/disorders-of-platelets/.

[43] S. M. Kawthalkar, Essentials of Hematology, p. 602, Gouridevi Institute of Medical Sciences and Hospitals, Rajbhand, West Bengal, 2020.
[38] P. Harrison, M. Robinson, R. Liesner et al., “The PFA-100: A Potential Rapid Screening Tool for the Assessment of Platelet Dysfunction,” *Clinical & Laboratory Haematology*, vol. 24, no. 4, pp. 225–232, 2002.

[39] Medscape, “What Is the Platelet Function Analyzer 100 (PFA-100) and How Is It Used in the Workup of Platelet Disorders?,” 2022, https://www.medscape.com/answers/201722-90211/what-is-the-platelet-function-analyzer-100-pfa-100-and-how-is-it-used-in-the-work-up-of-platelet-disorders.

[40] M. C. Berndt and R. K. Andrews, "Bernard-soulier syndrome," *Haematologica*, vol. 96, no. 3, pp. 355–359, 2011.

[41] F. Lanza, "Bernard-Soulier Syndrome (Hemorrhagicpurpura Thrombocytic Dystrophy)," *Orphanet Journal of Rare Diseases*, vol. 1, no. 1, pp. 46–6, 2006.

[42] J. P. Frontroth and E. J. Favaloro, “Ristocetin-induced platelet aggregation (RIPA) and RIPA mixing studies,” *Methods in Molecular Biology* (Clifton, N.J.), vol. 1646, pp. 473–494, 2017.

[43] R. Redaelli, A. R. Corno, L. Borroni et al., "Von Willebrand Factor Ristocetin Cofactor (VWF:RCo) Assay: Implementation on an Automated Coagulometer (ACL)," *Journal of Thrombosis and Haemostasis*, vol. 3, no. 12, pp. 2684–2688, 2005.

[44] R. Flaumenhaft and A. Sharda, "The Life Cycle of Platelet Granules," *F1000Research*, vol. 7, 2018.

[45] J. Y. Chen, Y. Yuan, and W. Li, "Sorting machineries: how platelet-dense granules differ from α-granules," *Bioscience Reports*, vol. 38, no. 5, Article ID BS20180458, 2018.

[46] A. Cuker, “Light transmission aggregometry,” *The Hematologist*, vol. 11, no. 2, 2014.

[47] P. J. Vinholt, M. Nybo, C. B. Nielsen, and A. M. Hvas, “Light Transmission Aggregometry Using Pre-Coated Microtiter Plates and a Victor X5 Plate Reader,” *PLOS ONE*, vol. 12, no. 10, Article ID e0185675, 2017.

[48] Ya A. Naimushin and A. V. Mazurov, "Ability of Different Glycoprotein Ib-IIIa Ligands to Support Platelet Aggregation Induced by Activating Antibody CRC54," *Biochemistry (Moscow)*, vol. 70, no. 7, pp. 782–789, 2005.

[49] M. Solh, T. Solh, and A. Botsford, "Glanzmann’s thrombasthenia: pathogenesis, diagnosis, and current and emerging treatment options," *Journal of Blood Medicine*, vol. 6, no. July, pp. 219–227, 2015.

[50] D. Mutreja, R. K. Sharma, A. Purohit, M. Aggarwal, and R. Saxena, "Evaluation of Platelet Surface Glycoproteins in Patients with Glanzmann Thrombasthenia: Association with Bleeding Symptoms," *The Indian Journal of Medical Research*, vol. 145, no. 5, pp. 629–634, 2017.

[51] J. Lee, J. K. Kim, J. H. Kim et al., “Recovery Time of Platelet Function After Aspirin Withdrawal,” *Current Therapeutic Research*, vol. 76, no. December, pp. 26–31, 2014.

[52] L. I. Thorsen, F. Brossad, G. Gogstad, K. Sletten, and N. O. Solum, "Competitions between Fibrinogen with Its Degradation Products for Interactions with the Platelet-Fibrinogen Receptor," *Thrombosis Research*, vol. 44, no. 5, pp. 611–623, 1986.

[53] F. Rodeghiero, A. Tosetto, T. Abshire et al., "ISTH/SSC Bleeding Assessment Tool: A Standardized Questionnaire and a Proposal for a New Bleeding Score for Inherited Bleeding Disorders," *Journal of Thrombososis and Haemostasis*, vol. 8, no. 9, pp. 2063–2065, 2010.

[54] Medscape, "What Is the Platelet Function Analyzer 100 (PFA-100) and How Is It Used in the Workup of Platelet Disorders?,” 2022, https://www.medscape.com/answers/201722-90211/what-is-the-platelet-function-analyzer-100-pfa-100-and-how-is-it-used-in-the-work-up-of-platelet-disorders.

[55] M. Adler, J. Kaufmann, L. Alberio, and M. Nagler, “Diagnostic utility of the ISTH bleeding assessment tool in patients with suspected platelet function disorders,” *Journal of Thrombosis and Haemostasis*, vol. 17, no. 7, pp. 1104–1112, 2019.

[56] M. R. Fasulo, E. Biguzzi, M. Abbattista et al., “The ISTH bleeding assessment tool and the risk of future bleeding,” *Journal of Thrombosis and Haemostasis*, vol. 16, no. 1, pp. 125–130, 2018.

[57] Ash Publications, “Testing the Testing Tool: ISTH Bleeding Assessment Accurately Predicts Patients With Platelet Function Disorders ASH Clinical News American Society of Hematology,” 2022, https://ashpublications.org/ashclinicalnews/news/4726/Testing-the-Testing-Tool-ISTH-Bleeding-Assessment.

[58] A. Pathare, S. Al Omrani, F. Al Hajri, N. Al Obaidani, B. Al Balushi, and K. Al Falahi, “Bleeding Score in Type 1 von Willebrand Disease Patients Using the ISTH-BAT Questionnaire,” *International Journal of Laboratory Hematology*, vol. 40, no. 2, pp. 175–180, 2018.

[59] S. Arif, A. S. Khan, and N. D. Afiz Raza Khan, “Changes in fibrinogen level in liver cirrhosis,” 2002, https://applications.emro.who.int/imemrf/J_Ayub_Med_Coll_Abbotabad_Pak/j_Ayub_Med_Coll_Abbotabad_Pak_2002_14_2_19.21.pdf.

[60] J. L. Kujovic, “Coagulopathy in Liver Disease: A Balancing Act,” *Hematology*, vol. 2015, no. 1, pp. 243–249, 2015.

[61] T. Lisman, C. Weetering, G. Philip, and De Groot, “Platelet Aggregation: Involvement of Thrombin and Fibrin(Ogen),” *Frontiers in Bioscience*, vol. 10, no. 1-3, pp. 2504–2517, 2005.

[62] P. E. Gatgan, C. Sheehan, L. Williams, V. Ploplis, U. Hearty, and C. Lowry, “A rapid latent agglutination assay for the determination of plasma fibrinogen,” *Blood Coagulation & Fibrinolysis*, vol. 1, no. 5, pp. 465–468, 1990.

[63] L. J. Stang and L. G. Mitchell, “Fibrinogen,” *Methods in Molecular Biology* (Clifton, N.J.), vol. 992, pp. 181–192, 2013.

[64] Healthline, “Fibrin degradation products (FDP): what is it?,” 2022, https://www.healthline.com/health/fibrin-degradation-products.

[65] R. B. Ford and E. M. Mazaferro, “Laboratory diagnosis and test protocols,” *Elsevier Public Health Emergency Collection*, Kirk and Bistner’s Handbook of Veterinary Procedures and Emergency Treatment, 9th edition, pp. 573–642, 2012.

[66] L. Meena, S. Kumar, S. Sinha, A. Bharti, V. Gupta, and J. Shukla, “A Study to Determine the Prevalence, Clinical Profile and Incidence of Formation of Inhibitors in Patients of Hemophilia in North Eastern Part of India,” *Journal of Family Medicine and Primary Care*, vol. 8, no. 7, p. 2463, 2019.

[67] S. Heinz and J. Braspenning, “Measurement of Blood Coagulation Factor Synthesis in Cultures of Human Hepatocytes,” *Methods in Molecular Biology* (Clifton, N.J.), vol. 1250, no. January, pp. 309–316, 2015.

[68] L. Amitrano, M. A. Guardascione, V. Brancaccio, and A. Balzano, “Coagulation disorders in liver disease,” *Seminars in Liver Disease*, vol. 22, no. 1, pp. 083–096, 2002.

[69] E. F. Mammen, “Coagulation Defects in Liver Disease,” *Medical Clinics of North America*, vol. 78, no. 3, pp. 545–554, 1994.

[70] A. J. D’Alessandro, “Vitamin K and its rôle in blood coagulation,” *The American Journal of Surgery*, vol. 57, no. 1, pp. 104–111, 1942.

[71] M. Haddadin, M. Al-Sadawi, S. Madanat, D. S McKenzie, R. Lewis, and S. I. McFarlane, “A Case Report of Intraoperative Coagulopathy Secondary to Chronic Vitamin K Deficiency,” *American Journal of Medical Case Reports*, vol. 7, no. 8, pp. 167–169, 2019.
[72] C. Kelly, S. Sattler, and A. Schwartz, “Coagulopathy Secondary to Vitamin K Deficiency Caused by Severe Diarrhea,” The American Journal of Emergency Medicine, vol. 35, no. 4, 2017.

[73] A. Girolami, S. Ferrari, E. Cosi, C. Santarossa, and M. L. Randi, “Vitamin K-dependent coagulation factors that may Be responsible for Both bleeding and thrombosis (FII, FVII, and FIX),” Clinical and Applied Thrombosis/Hemostasis, vol. 24, no. 9_suppl, pp. 425–475, 2018.

[74] A. Undas, K. E. Brummel-Ziedins, and K. G. Mann, “Antithrombotic Properties of Aspirin and Resistance to Aspirin: Beyond Strictly Antiplatelet Actions,” Blood, vol. 109, no. 6, pp. 2285–2292, 2007.

[75] H. T. Benzson, M. Park, R. J. McCarthy, M. C. Kendall, and P. F. Lindholm, “Mixing studies in patients with prolonged activated partial thromboplastin time or Prothrombin time,” Anesthesia & Analgesia, vol. 128, no. 6, pp. 1089–1096, 2019.

[76] J. Chen, B. Phillips, and W. L. Chandler, “Evaluation of Prothrombin time and activated partial thromboplastin time mixing studies using an estimated factor correction method,” Blood Coagulation & Fibrinolysis, vol. 27, no. 1, pp. 90–96, 2016.

[77] LabCE, “Interpreting the Mixing Study Results - LabCE.com, Laboratory Continuing Education,” 2022, https://www.labce.com/spg296340_interpreting_the_mixing_study_results.aspx.

[78] P. Mehta and R. R. Anil Kumar, Hemophilia, Brenner’s Encyclopedia of Genetics, London, UK, 2021.

[79] Orphanet Hemophilia, “Orphanet: Hemophilia,” 2022, https://www.orpha.net/consor/cgi-bin/OC_Exp.php?Lng=G&Expert=448.

[80] U. Budde, H. J. Metzner, and H. G. Müller, “Comparative analysis and classification of von Willebrand factor/factor VIII concentrates: impact on treatment of patients with von Willebrand disease,” Seminars in Thrombosis and Hemostasis, vol. 32, no. 6, pp. 626–635, 2006.

[81] Mayo Clinic, “Von Willebrand Disease-Symptoms and Causes-Mayo Clinic,” 2022, https://www.mayoclinic.org/diseases-conditions/von-willebrand-disease/symptoms-causes/syc-20354978.

[82] Rare Diseases, “Hemophilia B-NORD (National Organization for Rare Disorders),” 2022, https://rarediseases.org/rare-diseases/hemophilia-b/.

[83] S. Duga and O. Salomon, “Congenital factor XI deficiency: an update,” Seminars in Thrombosis and Hemostasis, vol. 39, no. 06, pp. 621–631, 2013.

[84] A. Kakade, T. Panchanadikar, and Y. Kulkarni, “Rare Case of Combined Factor V and Factor X Deficiency in Pregnancy: Presenting as Secondary Postpartum Haemorrhage in First Pregnancy and Successful Outcome in Second Pregnancy,” Obstetric Medicine, vol. 6, no. 3, pp. 134–135, 2013.

[85] A. M. H. P. van den Besselaar, “Principles of coagulation factor assays, coagulation and blood transfusion,” Developments in Hematology and Immunology, vol. 26, pp. 165–174, 1991.

[86] B. H. Shaz and C. D. Hillyer, Cryoprecipitate and Fibrinogen Concentrates, Transfusion Medicine and Hemostasis: Clinical and Laboratory Aspects, New York, NY, USA, 2013.

[87] Emedicine.Medscape, “Thrombin Time: Reference Range, Interpretation, Collection and Panels,” 2022, https://emedicine.medscape.com/article/2086278-overview.

[88] M. A. Laffan and R. Manning, “Investigation of Haemostasis,” Dacie and Lewis Practical Haematology, 2012.

[89] H. Karapetian, “Reptilase Time (RT),” Methods in Molecular Biology (Clifton, N.J.), vol. 992, pp. 273–277, 2013.

[90] S. M. Kawthalkar, Essentials of Haematology, Gouridevi Institute of Medical Sciences and Hospitals, Rajbandh, West Bengal, 2016.

[91] S. Sallah, “Inhibitors to Clotting Factors,” Annals of Hematology, vol. 75, no. 1–2, pp. 1–7, 1997.

[92] A. D. Ma and D. Carrizosa, “Acquired Factor VIII Inhibitors: Pathophysiology and Treatment,” Hematology, vol. 2006, no. 1, pp. 432–437, 2006.

[93] D. H. Scandella, “Properties of Anti-Factor VIII Inhibitor Antibodies in Hemophilia A Patients,” Seminars in Thrombosis and Hemostasis, vol. 26, no. Number 02, pp. 137–142, 2000.

[94] C. Witmer and G. Young, “Factor VIII Inhibitors in Hemophilia A: Rationale and Latest Evidence,” Therapeutic Advances in Hematology, vol. 4, no. 1, pp. 59–72, 2013.

[95] D. Castellone, “Inhibitor identification in the coagulation laboratory: table 1,” Laboratory Medicine, vol. 44, no. 4, pp. e118–20, 2013.

[96] R. J. M. Orin, “The Role of Phospholipids in Platelet Function,” Annals of Clinical and Laboratory Science, vol. 10, no. 6, 1980.

[97] M. Galli, D. Luciani, G. Bertolini, and T. Barbui, “Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature,” Blood, vol. 101, no. 5, pp. 1827–1832, 2003.

[98] D. A. Triplett, “Use of the Dilute Russell Viper Venom Time (DRVVT): Its Importance and Pitfalls,” Journal of Autoimmunity, vol. 15, no. 2, pp. 173–178, 2000.

[99] J. S. Dlott and R. A. S. Roubey, “Drug-induced lupus anticoagulants and antiphospholipid antibodies,” Current Rheumatology Reports, vol. 14, no. 1, pp. 71–78, 2012.

[100] H. Wada, “Disseminated Intravascular Coagulation,” Clinica Chimica Acta, vol. 344, no. 1–2, pp. 13–21, 2004.

[101] H. Asakura, “Classifying types of DIC: clinical features and animal models, Rinsho Ketsukei The Japanese Journal of Clinical Hematology, vol. 57, no. 4, pp. 397–404, 2016.

[102] S. Gando, M. Levi, H. Cheng, and Toh, “Disseminated intravascular coagulation,” Nature Reviews. Disease Primers, vol. 2, no. June, 2016.

[103] NHLBI, “Blood clotting disorders-disseminated intravascular coagulation (DIC) | NHLBI, NIH,” 2022, https://www.nhlbi.nih.gov/health/disseminated-intravascular-coagulation.

[104] E. Morishita, “Diagnosis and Treatment of Microangiopathic Hemolytic Anemia,” (Rinsho Ketsukei) The Japanese Journal of Clinical Hematology, vol. 56, no. 7, pp. 795–806, 2015.

[105] Msmanuals, “Microangiopathic Hemolytic Anemia - Hematology and Oncology - MSD Manual Professional Edition,” 2022, https://www.msdmanuals.com/professional/hematology-and-oncology/anemias-caused-by-hemolysis/microangiopathic-hemolytic-anemia.

[106] J. F. Lesesve, M. Martin, C. Banasiak et al., “Schistocytes in Disseminated Intravascular Coagulation,” International Journal of Laboratory Hematology, vol. 36, no. 4, pp. 439–443, 2014.

[107] C. S. Chapman, N. Akhtar, S. Campbell, K. Miles, J. O’Connor, and V. E. Mitchell, “The use of D-dimer assay by enzyme immunoassay and latex agglutination techniques in the diagnosis of deep vein thrombosis,” Clinical & Laboratory Haematology, vol. 12, no. 1, pp. 37–42, 2008.

[108] M. J. Elms, I. H. Bunce, P. G. Bundesen et al., “Rapid detection of cross-linked fibrin degradation products in plasma...
using monoclonal antibody-coated latex particles,” *American Journal of Clinical Pathology*, vol. 85, no. 3, pp. 360–364, 1986.

[109] S. Y. Kim, Ji E. Kim, H. K. Kim, I. Kim, S. S. Yoon, and S. Park, “Higher Prognostic Value of Soluble Fibrin Complexes than D-Dimer and Fibrin Degradation Product for Disseminated Intravascular Coagulation in Patients with Liver Cirrhosis,” *Blood Coagulation & Fibrinolysis*, vol. 24, no. 2, pp. 150–156, 2013.

[110] V. Musumeci, “Ethanol Gelation Test and Protamine Sulfate Test in Diagnosis of Intravascular Coagulation,” *Scandinavian Journal of Haematology*, vol. 24, no. 2, pp. 150–202, 2009.

[111] G. B. Thurston, “Viscoelasticity of Human Blood,” *Biophysical Journal*, vol. 12, no. 9, pp. 1205–1217, 1972.

[112] S. Vig, A. Chitole, D. Bevan, A. Halliday, and J. A. Dormandy, “Thromboelastography,” *Hematology*, vol. 6, no. 3, pp. 205–213, 2001.

[113] A. R. Hobson, R. A. Agarwala, R. A. Swallow, K. D. Dawkins, and N. P. Curzen, “Thrombelastography: Current Clinical Applications and Its Potential Role in Interventional Cardiology,” *Platelets*, vol. 17, no. 8, pp. 509–518, 2009.

[114] E. Bose and M. Hravnak, “Thromboelastography: a practice summary for nurse practitioners treating hemorrhage,” *The Journal for Nurse Practitioners*, vol. 11, no. 7, pp. 702–709, 2015.

[115] Litfl, “Thromboelastogram (TEG) • LITFL • CCC Investigations,” 2022, https://litfl.com/thromboelastogram-teg/.

[116] D. Govil and D. Pal, “Point-of-Care Testing of Coagulation in Intensive Care Unit: Role of Thromboelastography,” *Indian Journal of Critical Care Medicine: Peer-Reviewed, Official Publication of Indian Society of Critical Care Medicine*, vol. 23, no. Suppl 3, pp. S202–S206, 2019.

[117] L. T. Da Luz, B. Nascimento, A. K. Shankarakutty, S. Rizoli, N. K. Adhkari, and J. Adhkari, “Effect of Thrombelastography (TEG®) and Rotational Thromboelastometry (ROTEM®) on Diagnosis of Coagulopathy, Transfusion Guidance and Mortality in Trauma: Descriptive Systematic Review,” *Critical Care*, vol. 18, no. 5, p. 518, 2014.

[118] H. J. Rogers, M. O. Nakashima, and K. Kottke-Marchant, “Hemostasis and Thrombosis,” *Hematopathology: A Volume in the Series: Foundations in Diagnostic Pathology*, vol. 57, 2018.